Overview

Personalized Theratyping Trial

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.

Phase:

Early Phase 1

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Ivacaftor